Archer is now part of IDT, bringing the future of precision oncology to cancer care. The transaction was completed December 2022. Learn more here. 

Precision oncology
in your lab

Archer is now IDT. The combination was completed in December 2022 to bring comprehensive cancer genetics and precision oncology to patients worldwide.

The global fight against cancer requires advanced molecular detection products that are accurate, actionable, easy-to-use and available worldwide.

Our products and services

Investigational Liquid-biopsy Based Cancer Recurrence Detection

Clinical Research Services

Co-development Services
We aim to address barriers to bringing precision oncology to patients, anywhere
We are global
We provide expansive
access
menu home-icon-silhouette remove-button twitter linkedin-1 facebook-circular-logo right